Core Insights - Scienture Holdings, Inc. is focused on enhancing patient care through the development and commercialization of novel pharmaceutical products, specifically highlighting the upcoming launch of REZENOPY and the growth of ARBLI [1][4][17] Group 1: Product Developments - ARBLI, the first FDA-approved ready-to-use oral liquid formulation of losartan, addresses a significant market need in the U.S. losartan market, which has an annual size of approximately $241 million and 72 million prescriptions [2][8] - The company plans to launch REZENOPY, an opioid overdose emergency treatment, in Q2 2026, targeting a market with annual sales of $143 million and 9.2 million prescriptions [4][14] Group 2: Market Access and Growth Initiatives - Scienture has implemented various initiatives to expand access to ARBLI, including securing GPO agreements and expanding formulary inclusion, which will increase patient and provider access [4][5] - The company has established partnerships with BlinkRx to enhance patient access and adherence through a digital pharmacy platform [5] Group 3: Financial Performance and Outlook - Scienture reported a significant improvement in its balance sheet, with a cash position of approximately $7.0 million as of December 31, 2025, and a reduction in outstanding debt [7] - The company anticipates continued growth in ARBLI prescription volumes and improved commercial efficiency, expecting Q1 2026 to reflect the momentum built in prescriber adoption and patient demand [6][7]

Vitiligo is a chronic, autoimmune disease that imposes a significant psychosocial burden, profoundly affecting an individual's confidence, identity and daily life. NSV, the most common form of vitiligo (afflicting approximately 84% of patients), is marked by symmetrical and bilateral depigmented white patches and is prone to unpredictable progression even after long periods of stability. Vitiligo management is anchored in three primary treatment goals: disease stabilization, re-pigmentation, and maintaining ...

Eli Lilly and Co. (NYSE:LLY) is set to report fourth-quarter earnings on Feb. 4 before the opening bell, with Wall Street forecasting a significant revenue beat driven by its blockbuster weight-loss and diabetes drugs.While topline expectations are high, surging research costs could challenge the company's ability to hit ambitious profit targets.Revenue Expectations Vs. GuidanceAnalysts project fourth-quarter revenue of $17.90 billion, as per Benzinga, a figure that exceeds the implied ceiling of management ...

Group 1 - Sanofi SA is considered one of the best cheap stocks to buy for 2026 according to Citi Research, which initiated coverage of six large European pharmaceutical stocks including Sanofi [1] - Citi assigned Sanofi a Neutral rating with a price target of €85, indicating concerns about the company's drug development progress and a weakened long-term growth outlook due to pipeline setbacks [2][3] - The current valuation of Sanofi is approximately 10 times expected 2026 earnings, reflecting the setbacks in its pipeline, and the market is unlikely to reward the stock with a higher multiple without tangible evidence of improvement [3] Group 2 - Sanofi reported positive results for its experimental medicine amlitelimab in Phase 3 clinical studies for moderate-to-severe atopic dermatitis, with data coming from two major global trials, SHORE and COAST 2 [4] - The results from the studies indicate that amlitelimab was generally well tolerated, with side effects consistent with previous findings [4] - Sanofi operates in various segments including specialty care, vaccines, and general medicines, focusing on the research, development, manufacturing, and marketing of pharmaceutical products [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 補體參與介導的腎臟疾病（Complement - mediated kidney disease,「CMKD」）是一類由 補體系統異常激活直接或間接介導的腎臟疾病，涵蓋多種原發性和繼發性腎小球疾病。 根據發病機制，CMKD可分為兩大類：（1）由補體系統異常活化直接介導的腎病，包 括C3腎小球病（C3 glomerulopathy, 「C3G」）、非典型溶血尿毒癥綜合徵、免疫複合 * 僅供識別 1 自願性及業務進展公告 創新藥補體因子B抑制劑CMS-D017 獲得補體參與介導的腎臟疾病適應症 藥物臨床試驗批准通知書 China Medical System Holdings Limited（「本公司」，連同其附屬公司統稱為「本集團」） 欣然宣佈，於二零二六年二月三日，本集團自主研發的創新藥CMS-D017膠囊 （「CMS-D017」或「產品」）獲得中國國家藥品監督管理局（「NMPA」）簽發的藥 物臨床試驗批准通 ...

Core Insights - MIRA Pharmaceuticals has initiated dosing in the final cohort of its Phase 1 clinical trial for Ketamir-2, an oral NMDA receptor antagonist, with plans to complete the trial by the end of Q1 2026 [1] - The company is preparing for a Phase 2a study targeting chemotherapy-induced peripheral neuropathy (CIPN) and aims to submit the protocol to the FDA after completing Phase 1 [1] - MIRA plans to pursue FDA Fast Track designation for Ketamir-2 due to the significant unmet medical need in CIPN treatment [1] Phase 1 Progress and Phase 2a Development Plans - The ongoing Phase 1 study is randomized, double-blind, and placebo-controlled, focusing on safety, tolerability, and pharmacokinetics of Ketamir-2 [1] - So far, 50 healthy volunteers have been dosed, with 6 subjects remaining in the final cohort [1] - No serious adverse events have been reported, supporting the advancement of the program [1] - The Phase 2a study is expected to begin in Q2 2026, pending regulatory feedback [1] Unmet Medical Need in CIPN - CIPN is a common complication of cancer treatment, leading to chronic nerve pain and significantly impairing quality of life [1] - There are currently no FDA-approved treatments for CIPN, with management relying on off-label therapies that often provide limited benefits [1] - Ketamir-2 aims to offer a safer, orally administered alternative without the psychoactive effects associated with existing treatments [1] Strategic Partnering and Scientific Engagement - MIRA will attend the BIO Partnering Investment & Growth Summit in March 2026 to engage with pharmaceutical companies for potential partnerships [1] - The company will present Phase 1 data on Ketamir-2 at the AACR Annual Meeting in April 2026 [1] Pipeline Update Beyond Ketamir-2 - MIRA is also developing two preclinical programs, SKNY-1 and MIRA-55, both undergoing CMC optimization [1] - SKNY-1 targets weight loss and nicotine addiction, designed to avoid CNS-related adverse effects [1] - MIRA-55 has shown analgesic activity comparable to morphine and significant anti-inflammatory effects in preclinical models [1]

Core Insights - Pfizer announced a positive study outcome for a weight-loss drug candidate, indicating potential growth in this therapeutic area [1] - The company also projected a decline in profits, attributing this to the pricing and tariff policies implemented during the Trump administration [1] Group 1: Drug Development - Pfizer's weight-loss drug candidate has shown promising results in a recent study, which could enhance its portfolio in the obesity treatment market [1] Group 2: Financial Outlook - The company forecasts a profit decline, highlighting the adverse effects of the Trump administration's policies on drug pricing and tariffs [1]

Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s recent game plan. Cramer highlighted what “drives the stock,” as he remarked: Wednesday morning, Eli Lilly reports. Its earnings haven’t been the propellant here. What drives the stock are new reports on GLP-1 clinical trials. But Lilly could announce some new data, and that could get the stock rolling. Stock market data. Photo by Alesia Kozik on Pexels Eli Lilly and Company (NYSE:LLY) develops and markets medicines for diabetes, ob ...

Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s recent game plan. Cramer had mixed feelings about the stock, as he stated: On the other hand, I worry about Pfizer because while its stock has a terrific yield, I haven’t seen anything of late that would make me feel there’s a new blockbuster here that could move the needle. Although I was thinking about when I saw Verizon do that today, which was also a bond that turned into a stock… it maybe could happen to Pfizer. Photo by Spencer Davis on ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s recent game plan. Cramer noted that he likes the stock, as he said: Merck has a lot to talk about, namely, some real wins from its bountiful acquisition spree. I like the stock. A little too heavy on Keytruda right now, but I think it can spread out the wealth. Photo by Adam Nowakowski on Unsplash Merck & Co., Inc. (NYSE:MRK) is a healthcare company that provides a wide range of human and veterinary pharmaceuticals, vaccines, and health ...